$JNJ

Generating a unique summary for JNJ…

AI-generated for information only — not investment advice.

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Institutions hold 76.89% · insiders 0.05% · 5,819 institutions

Consensus score 1.91 (1 = strong buy, 5 = sell) · mean target 275.64

• UBSBuymain2026-09-02
• GuggenheimBuymain2026-08-06
• Wells FargoOverweightmain2026-08-03
• GuggenheimBuyreit2026-07-17
• Raymond JamesOutperformmain2026-07-16
• RBC CapitalOutperformreit2026-07-16
• Wells FargoOverweightmain2026-07-16
• Morgan StanleyOverweightmain2026-07-16
• TD CowenBuymain2026-07-13
• RBC CapitalOutperformmain2026-07-13

Next report: 2026-10-13

• N-PXAnnual Report of Proxy Voting Record of Registered Management Investment Companies filed on Form N-PX2026-08-11Open
• 8-KCorporate Changes & Voting Matters2026-08-04Open
• 8-KCorporate Changes & Voting Matters2026-07-29Open
• 8-KCorporate Changes & Voting Matters2026-07-28Open
• 10-QPeriodic Financial Reports2026-07-23Open
• 8-KCorporate Changes & Voting Matters2026-07-15Open
• 11-KAnnual report of employee stock purchase2026-06-25Open
• SDSpecialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)2026-05-27Open
• 8-KCorporate Changes & Voting Matters2026-04-28Open
• 10-QPeriodic Financial Reports2026-04-22Open

• Lilly vs. J&J: Betting on Breakout Growth or Built-In Stability?

  Lilly and J&J offer distinct paths for investors, with strong growth, expanding pipelines and key headwinds shaping their outlooks.

  Mon, 07 Sep 2026 14:03:00 +0000

• Which Defensive Stock Has Dominated in 2026: Coca-Cola, Johnson & Johnson, or Procter & Gamble?

  Three defensive blue chips entered 2026 promising safety, but their returns split into wildly different tiers, and the reason one name lapped the others exposes a fault line in how investors define defensive in the first place.

  Mon, 07 Sep 2026 13:40:21 +0000

• 3 Dividend Kings Built to Keep Raising Your Income When Rates Rise

  Treasury yields near a one-year high are punishing most dividend stocks, but a handful of Dividend Kings kept signing bigger checks every single quarter without missing a beat. The question is whether their balance sheets can keep that streak alive.

  Sat, 05 Sep 2026 14:37:34 +0000

• Was JNJ Stock Rally Actually Its Own?

  Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbed, and its talc litigation now has a proposed ending. Both are real. The first does not explain a move that size, and the second is not finished.

  Fri, 04 Sep 2026 16:57:27 +0000

• Johnson & Johnson Is Boring Which Makes Its Dividend Nearly Perfect.

  Sixty-four straight years of dividend growth sounds like a headline, but the real story is what keeps that streak alive even as one of JNJ's biggest drugs faces a brutal competitive hit.

  Fri, 04 Sep 2026 13:04:20 +0000

• Is Johnson & Johnson (JNJ) Cheap After The Louisiana Talc Verdict?

  Johnson & Johnson (JNJ) is back in the spotlight after a Louisiana jury found the company liable in a talc related mesothelioma case, adding a fresh layer to its ongoing litigation risk. Against this backdrop, Johnson & Johnson’s recent 7 day share price return of 4.76% and 30 day share price return of 9.22% indicate that momentum has been building ahead of the Louisiana verdict and the latest FDA approval, while the 1 year total shareholder return of 59.27% and 5 year total shareholder...

  Fri, 04 Sep 2026 04:36:59 +0000

• Is Johnson & Johnson Stock Priced For More Growth Than It Has Guided?

  Johnson & Johnson (JNJ) has had a good year. The stock is up 56.5% over the past twelve months against 19.1% for the S&P 500, and at $271.19 sits at about 99% of its 52-week high. The business is still growing. The risk is that the current stock price discounts an acceleration well ahead of management's near-term guidance.

  Thu, 03 Sep 2026 15:24:52 +0000

• Global Surgical Robots Market to Reach $10.6 Billion in 2026, Driven by AI Integration and Minimally Invasive Surgery

  Report Features In-Depth Profiles of Abbott, Great Robotics, Intuitive Surgical, Johnson & Johnson, Medtronic, Panasonic, Renishaw, Siemens Healthineers, Smith+Nephew, Stryker, Zimmer Biomet, and FreehandDublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Surgical Robots Market by Offering of Surgical Robot Developers, Deployment Model, Type of Surgical Procedure Supported, Application Area, End Users and Key Geographical Regions - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.

  Mon, 07 Sep 2026 08:21:00 +0000